Drug intelligence / Profile preview

doxorubicin liposomal + melphalan + bortezomib

Development stage: Unknown
Lead developer: Johnson & Johnson
Modality: Small Molecules
Administration: Intravenous, Subcutaneous

Overview

This is a combination therapy regimen used in the treatment of multiple myeloma. It combines three active agents: pegylated liposomal doxorubicin (PLD, also known as Doxil), melphalan, and bortezomib (Velcade). This combination has been studied particularly in elderly newly diagnosed multiple myeloma patients. The regimen typically involves induction therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone followed by melphalan conditioning for stem cell transplantation.

Other names: pegylated liposomal doxorubicin + melphalan + bortezomibPLD + melphalan + bortezomib

Targets

TOP2A (DNA topoisomerase II)26S proteasomeDNA

Beyond the preview

Go deeper on doxorubicin liposomal + melphalan + bortezomib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on doxorubicin liposomal + melphalan + bortezomib.

Explore the full profile